WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H315271
CAS#: 83919-23-7 (furoate)
Description: Mometasone furoate acts as a prodrug of mometasone. In addition to its glucocorticoid activity, mometasone also has very potent progestogenic activity and acts as a partial agonist of the mineralocorticoid receptor. including the vehicle and the integrity of the epidermal barrier. Mometasone furoate reduces inflammation by causing several effects: (a) Reversing the activation of inflammatory proteins; (b) Activating the secretion of anti-inflammatory proteins; (c) Stabilizing cell membranes; (d) Decreasing the influx of inflammatory cells.
Hodoodo Cat#: H315271
Name: Mometasone furoate
CAS#: 83919-23-7 (furoate)
Chemical Formula: C27H30Cl2O6
Exact Mass: 520.14
Molecular Weight: 521.431
Elemental Analysis: C, 62.19; H, 5.80; Cl, 13.60; O, 18.41
Related CAS #: 83919-23-7 (furoate) 141646-00-6 (furoate hydrate) 105102-22-5 (Mometasone),
Synonym: ELOCON brand of mometasone furoate cream (0.1)
IUPAC/Chemical Name: (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
InChi Key: WOFMFGQZHJDGCX-ZULDAHANSA-N
InChi Code: InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
SMILES Code: O=C(C1=CC=CO1)O[C@]2(C(CCl)=O)[C@H](C)C[C@@]3([H])[C@]4([H])CCC5=CC(C=C[C@]5(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 521.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Youssef YM, Mahrouse MA, Mostafa EA. Plackett-Burman and face-centered composite designs for development and optimization of chromatographic method for the simultaneous determination of glycopyrronium, indacaterol and mometasone in their fixed dose combination inhaler - Green profile assessment. J Pharm Biomed Anal. 2023 Jun 27;234:115553. doi: 10.1016/j.jpba.2023.115553. Epub ahead of print. PMID: 37399700.
2: Kostikas K, Maspero JF, Chapman KR, Mezzi K, Jaumont X, Lawrence D, van Zyl- Smit R. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study. Respir Med. 2023 Jun 29:107334. doi: 10.1016/j.rmed.2023.107334. Epub ahead of print. PMID: 37392789.
3: Beebeejaun MT, Brown MB, Hutter V, Kravitz L, McAuley WJ. Skin permeation and penetration of mometasone furoate in the presence of emollients: An ex vivo evaluation of clinical application protocols. Skin Health Dis. 2023 Jan 20;3(3):e215. doi: 10.1002/ski2.215. PMID: 37275414; PMCID: PMC10233081.
4: Zimath P, Pinto S, Dias S, Rafacho A, Sarmento B. Zein nanoparticles as oral carrier for mometasone furoate delivery. Drug Deliv Transl Res. 2023 May 19. doi: 10.1007/s13346-023-01367-y. Epub ahead of print. PMID: 37208563.
5: Woehrle H, Mastoridis P, Stempel D, Kaye L, Vuong V, Mezzi K. Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany. Pulm Ther. 2023 Apr 30. doi: 10.1007/s41030-023-00225-z. Epub ahead of print. PMID: 37120785.
6: Ridolo E, Barone A, Nicoletta F, Paoletti G, Heffler E, Malvezzi L, Canonica GW. Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate. Expert Rev Clin Immunol. 2023 Jun;19(6):575-584. doi: 10.1080/1744666X.2023.2200165. Epub 2023 Apr 19. PMID: 37038974.
7: Niimi A, Kanemitsu Y, Tajiri T, Sumi K, Mikami T, Kondo N. Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy in patients with asthma: REACH study design. ERJ Open Res. 2023 Mar 27;9(2):00452-2022. doi: 10.1183/23120541.00452-2022. PMID: 37009022; PMCID: PMC10052813.
8: Cataldo Russomando A, Steinberg D, Gati I, Vogt Sionov R, Eliashar R, Friedman M, Gross M. Sinonasal Stent Coated with Sustained-Release Varnish of Mometasone Furoate Inhibits Pro-Inflammatory Cytokine Release from Macrophages: An In Vitro Study. Pharmaceutics. 2023 Mar 22;15(3):1015. doi: 10.3390/pharmaceutics15031015. PMID: 36986875; PMCID: PMC10051169.
9: Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study. Respir Med. 2023 May;211:107172. doi: 10.1016/j.rmed.2023.107172. Epub 2023 Mar 9. PMID: 36906187.
10: Zimath PL, Almeida MS, Bruxel MA, Rafacho A. Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats. Biochem Pharmacol. 2023 Apr;210:115486. doi: 10.1016/j.bcp.2023.115486. Epub 2023 Mar 7. PMID: 36893817.
11: Engineering JOH. Retracted: Treatment Effect of Mometasone Furoate Cream on Lichen Sclerosus et Atrophicus of External Genitalia in Boys and Its Correlation with Toll-Like Receptor 4 and Myeloid Differentiation Factor 88. J Healthc Eng. 2023 Jan 25;2023:9764362. doi: 10.1155/2023/9764362. PMID: 36741875; PMCID: PMC9891809.
12: van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma. J Asthma Allergy. 2023 Jan 20;16:123-134. doi: 10.2147/JAA.S392975. PMID: 36714049; PMCID: PMC9880009.
13: Fifer S, Toh L, Barkate H, Aggarwal V, Borade D, Gordonsmith RH, Wu W, Morgan C, Young K. Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study. Patient Prefer Adherence. 2023 Jan 15;17:141-151. doi: 10.2147/PPA.S389875. PMID: 36687019; PMCID: PMC9851056.
14: Mehmood Y, Shahid H, Barkat K, Ibraheem M, Riaz H, Badshah SF, Chopra H, Sharma R, Nepovimova E, Kuca K, Valis M, Emran TB. Designing of SiO2 mesoporous nanoparticles loaded with mometasone furoate for potential nasal drug delivery: Ex vivo evaluation and determination of pro-inflammatory interferon and interleukin mRNA expression. Front Cell Dev Biol. 2023 Jan 6;10:1026477. doi: 10.3389/fcell.2022.1026477. PMID: 36684440; PMCID: PMC9853011.
15: Lage NA, de Paiva MRB, Vasconcelos-Santos DV, Machado RR, Fialho SL, Silva- Cunha A. Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation. Pharmaceutics. 2023 Jan 5;15(1):193. doi: 10.3390/pharmaceutics15010193. PMID: 36678822; PMCID: PMC9863942.
16: Olopatadine/mometasone (Ryaltris) for allergic rhinitis. Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-14. doi: 10.58347/tml.2023.1668c. PMID: 36651792.
17: Baker A, Grobler A, Davies K, Griffiths A, Hiscock H, Kubba H, Peters RL, Ranganathan S, Rimmer J, Rose E, Rowe K, Simpson CM, Davidson A, Nixon G, Perrett KP. Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep- Disordered Breathing in Children: A Randomized Clinical Trial. JAMA Pediatr. 2023 Mar 1;177(3):240-247. doi: 10.1001/jamapediatrics.2022.5258. PMID: 36648937; PMCID: PMC9857783.
18: Jahani M, Akaberi M, Heidari T, Kamali H, Nejabat M, Rajabi O, Hadizadeh F. Simultaneous determination of mometasone furoate and calcipotriol in a binary mixture by validated HPLC and chemometric-assisted UV spectrophotometric methods and identification of degradation products by LC-MS. Iran J Basic Med Sci. 2023 Jan;26(1):37-47. doi: 10.22038/IJBMS.2022.65436.14396. PMID: 36594065; PMCID: PMC9790053.
19: Taléns-Visconti R, Perra M, Ruiz-Saurí A, Nácher A. New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases. Pharmaceutics. 2022 Nov 22;14(12):2558. doi: 10.3390/pharmaceutics14122558. PMID: 36559053; PMCID: PMC9786812.
20: Harugop AS, Havaldar RR, Patil PH. Comparison Between Effectiveness of Topical Mometasone Furoate Nasal Spray Versus Topical Fluticasone Furoate Nasal Spray in the Treatment of Chronic Rhinosinusitis: A One Year Hospital Based Study. Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):821-825. doi: 10.1007/s12070-020-01872-3. Epub 2020 May 6. PMID: 36452763; PMCID: PMC9702125.
